Olema Pharmaceuticals, Inc. (OLMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.75+0.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OLMA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue enrollment and data readout for Phase 3 OPERA-01 and OPERA-02 trials of palazestrant in metastatic breast cancer.
Stated as a priority in 2 of last 2 quarters. Management emphasized advancing Phase 3 OPERA-01 and OPERA-02 trials with top-line data from OPERA-01 expected in fall 2026 and ongoing enrollment in OPERA-02. Financials show increasing net losses reflecting clinical development spending, consistent with advancing late-stage trials. The trajectory matches management's stated focus on progressing these pivotal trials.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“CEO: 'We approach pivotal data from OPERA-01 and prepare for potential commercial launch.'”
“CEO: 'Top-line data from Phase 3 OPERA-01 trial anticipated this fall; OPERA-02 trial continues to enroll patients.'”
Execute clinical trial collaboration to evaluate OP-3136 with Bayer's darolutamide in metastatic prostate cancer.
Newly stated in 2026-Q2. Management announced a clinical trial collaboration with Bayer to evaluate OP-3136 combined with darolutamide in metastatic prostate cancer. This is the first clinical collaboration for OP-3136. Financials show continued investment in clinical development consistent with advancing OP-3136 programs. The priority is newly introduced and execution is in early stages.
Progress Phase 1 clinical study of OP-3136 including monotherapy and combination therapies in solid tumors.
Stated in 2 quarters including 2026-Q1 and 2026-Q2. Management highlighted initial Phase 1 clinical data for OP-3136 showing safety and anti-tumor activity, and ongoing enrollment in early-stage studies. Financials reflect increased R&D expenses consistent with advancing OP-3136 development. The trajectory shows progress consistent with management's stated development goals.
“CEO: 'Approach pivotal data from OPERA-01 and prepare for commercial launch; advancing OP-3136 in early-stage clinical studies.'”
Lease additional office and laboratory space to support company growth and operations.
Newly stated in 2026-Q2. Management disclosed entering a lease agreement for about 38,176 square feet of office and lab space to support growth. No prior quarters mention this expansion. Financials show ongoing net losses consistent with growth investments. The priority is newly introduced and execution is underway.
Appoint new director to Board to strengthen governance and expertise.
Newly stated in 2026-Q2. Management announced the appointment of Dr. Prakash Raman to the Board of Directors. This is a one-time event with no prior mentions. Financials do not directly reflect this priority. The priority is a recent governance enhancement.
Over the trailing year it converted 0.93x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.